PT-141
PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is a cyclic heptapeptide analogue of alpha-MSH that acts as a non-selective melanocortin receptor agonist. FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, it is the first and only pharmacological treatment for sexual desire in women. Research in men for erectile dysfunction and male HSDD is ongoing.
Mechanism of Action
PT-141 activates melanocortin receptors in the central nervous system — particularly MC3R and MC4R in the hypothalamus and limbic regions. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally through vascular mechanisms, PT-141 acts centrally on the neural circuits governing sexual desire and arousal.
MC4R activation in the hypothalamus increases dopamine release in the medial preoptic area (mPOA) — a brain region critical for sexual motivation and behaviour. This centrally-mediated mechanism means PT-141 affects desire and motivation, not just physical arousal response.
The central mechanism of action explains why PT-141 may be effective in cases where PDE5 inhibitors fail (e.g., desire disorders, psychogenic dysfunction) and why its effects include enhanced fantasy, motivation, and spontaneous arousal rather than purely mechanical response.
Research Evidence
PT-141 (Bremelanotide) was FDA-approved in 2019 based on two Phase 3 trials in premenopausal women with HSDD. Research in men demonstrates pro-erectile effects and is ongoing.
Bremelanotide for Female Hypoactive Sexual Desire Disorder (Phase 3)
Two pivotal Phase 3 trials (n=1,267 premenopausal women with HSDD): SC bremelanotide significantly increased satisfying sexual events and desire scores vs placebo at 24 weeks, with statistically significant distress reduction. FDA approved on this basis.
Typical Research Protocol
Onset typically 45–60 minutes. Duration 4–12 hours. Do not use more than once per 24 hours. Males typically use the same 1.75mg dose; some research protocols used higher doses (2mg) in erectile dysfunction studies.
Safety Profile
Reported Side Effects
- Nausea (40%)
- Flushing (20%)
- Headache (11%)
- Injection site bruising
- Transient blood pressure increase
- Hyperpigmentation (face/gums) with frequent use
Contraindications
- Uncontrolled hypertension
- Known cardiovascular disease
- Use of PDE5 inhibitors (synergistic BP drop)
- Pregnancy
- History of pigmentation disorders
Frequently Asked Questions
Can men use PT-141?
PT-141 is FDA-approved only for HSDD in premenopausal women, but research in men (primarily for erectile dysfunction) demonstrates clear pro-erectile effects via the central MC4R pathway. Off-label use in men is not uncommon. It may be particularly useful for psychogenic ED where PDE5 inhibitors are ineffective. Male dosing in trials used 0.5–2mg SC.
Does PT-141 cause permanent skin darkening?
At the approved dose (1.75mg) used as-needed, significant hyperpigmentation is uncommon. Chronic high-frequency use can cause darkening of the face, breasts, and gums via MC1R (melanogenic receptor) stimulation. Occasional/as-needed use at approved doses carries low hyperpigmentation risk.
How is PT-141 different from Viagra (sildenafil)?
Sildenafil (Viagra) and tadalafil (Cialis) work peripherally by inhibiting PDE5 to increase blood flow to genital tissue — they require sexual stimulation to work and primarily address mechanical arousal. PT-141 acts centrally in the brain (hypothalamus, MC4R) to increase sexual desire, motivation, and arousal drive itself. PT-141 may be effective where PDE5 inhibitors fail and addresses the desire component that PDE5 drugs do not.
How long does PT-141 last?
PT-141 effects typically begin within 45–60 minutes of SC injection and can last 4–12 hours. The window varies by individual — some experience effects for up to 12+ hours, which is why the FDA label cautions against using it more than once per 24-hour period. The elevated blood pressure effect (which may last 12 hours) is the primary reason for the dosing interval restriction.
Can PT-141 be used to treat female arousal disorder (FSAD)?
HSDD (hypoactive sexual desire disorder) and FSAD (female sexual arousal disorder) are related but distinct conditions. Vyleesi is specifically approved for HSDD (insufficient desire). For FSAD (impaired physical arousal), flibanserin (Addyi) is the other approved option. Research data on PT-141 shows improvements in both desire and arousal measures in women, suggesting benefit beyond pure desire, but the FDA indication is specifically for HSDD.
Key Research References
- Kingsberg SA et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol.
- Safarinejad MR, Hosseini SY. (2008). Intranasal bremelanotide for male erectile dysfunction. J Urol.
Explore more Recovery research compounds
Browse Recovery →